CureMeAbroad, a Pune-based AI-powered medical tourism discovery platform, has announced the close of its $600,000 pre-seed funding round.
The round included participation from investors such as Dr Roman Saini, co-founder of Unacademy and an AIIMS-trained physician; Himanshu Ratnoo, former CEO of Cars24 India; Kunal Gupta, co-founder and CEO of EMotorad; Devaiah Bopanna, co-founder of Moonshot; Vikrant Potnis, founder of the Indian Academy of Venture Capital (IAVC) and FundEnable; and AIRA Buildon.
CureMeAbroad was founded in June 2025 by Aditya Oza and Mikhail Bohra, targeting the cross-border medical travel segment, which the founders describe as underdeveloped within the broader healthcare market.
The global medical tourism market is projected to reach $174 billion by 2035, according to Global Market Insights. An estimated 14 million patients travel abroad for medical treatment each year.
According to the founders, the gap between interest and completed treatments points to structural challenges in the sector, including limited pricing transparency, dependence on informal intermediaries, unverified provider networks, and gaps in post-treatment support.
"There is no Booking.com for medical tourism, and for an industry touching 14 million lives every year, that is not a gap in the market, it is a failure of the global healthcare system," said Aditya Oza, CEO of CureMeAbroad.
"Patients should not be making the biggest decisions of their lives on forwarded WhatsApp messages. We set out to build the trust layer that the category has been missing. This is one of those rare problems where the impact is measured in millions of lives, and billions of dollars, and our ambition for CureMeAbroad is genuinely global," he added.
The startup said its AI-enabled platform includes a directory of more than 6,000 hospitals across 47 countries and 45 specialties. It claims to works with more than 380 accredited partner hospitals across medical travel destinations including Mexico, Turkey, Thailand, India and Georgia.
"That conviction is rooted in a track record Aditya's earliest backers have already lived through. "Backing Aditya again was the easiest decision I have had to make as an investor," said Kunal Gupta, co-founder and CEO of EMotorad.
"I worked alongside him for years at EMotorad. I watched him take a Pune startup with no capital and no distribution and help turn it into a globally recognised brand across 18 countries. The same instincts that worked there, thinking global from day one, treating consumer trust as the moat, obsessing over detail, are exactly what medical tourism has been waiting for. And the current traction in two quarters tells you he has already translated those instincts into this new category," he said.
CureMeAbroad will use the fresh capital to double down on deeper technology investments, expanding the AI cost estimator, clinical matching models, and the multilingual patient intelligence layer that powers the discovery engine.
Additionally, the startup will accelerate growth across target source markets, beginning with the GCC, UK, and Africa corridors.
"This round is about going deeper on tech, sharper on team, and wider on growth," said Aditya.
The startup is concurrently in active conversations with institutional investors for its seed round.